Comparisons between tumor burden and other prognostic factors that influence survival of patients with non‐small cell lung cancer treated with immune checkpoint inhibitors
View Full Paper
Ask AI
Bookmark
Share
Abstract
TB is a useful, clinically measurable prognostic factor of survival in NSCLC patients treated with ICIs.
Discussion
No takes yet. Share an insight, caveat, or question.